⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL939613 | 1.00 | — | — | |
| SCHEMBL4356389 | 1.00 | — | — | |
| SCHEMBL37819 | 1.00 | — | — | |
| SCHEMBL591561 | 0.81 | — | — | |
| SCHEMBL302739 | 0.81 | — | — | |
| SCHEMBL11516730 | 0.81 | — | — | |
| SCHEMBL524702 | 0.79 | — | — | |
| SCHEMBL302385 | 0.79 | — | — | |
| SCHEMBL4350655 | 0.74 | ATF4 (0.30) | — | |
| SCHEMBL28143526 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4376830-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREATMENT OF RENAL DISEASES IN NON-HUMAN MAMMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| CN-117715639-A | Use of SGLT-2 inhibitors for the prevention and/or treatment of kidney disease in non-human mammals | 勃林格殷格翰动物保健有限公司 | 2024-03-15 | — | — | CN | claimed |
| CN-117715640-A | Use of SGLT-2 inhibitors for preventing and/or treating heart diseases in non-human mammals excluding felines, particularly canines | 勃林格殷格翰动物保健有限公司 | 2024-03-15 | — | — | CN | claimed |
| US-20240050456-A1 | USE OF SGLT-2 INHIBITORS FOR THE PREVENTION AND/OR TREAT-MENT OF CARDIAC DISEASES IN FELINES | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2024-02-15 | — | — | US | claimed |
| WO-2023227492-A1 | AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-11-30 | — | — | WO | claimed |
| US-20230381101-A1 | AQUEOUS PHARMACEUTICAL COMPOSITIONS COMPRISING SGLT-2 INHIBITORS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-11-30 | — | — | US | claimed |
| US-20230338406-A1 | USE OF SGLT-2 INHIBITORS IN THE DRYING-OFF OF NON-HUMAN MAMMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-10-26 | — | — | US | claimed |
| EP-3862003-B1 | AN SGLT-2 INHIBITOR FOR USE IN THE TREATMENT OF A METABOLIC DISORDER IN FELINE ANIMALS | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-10-25 | — | — | EP | claimed |
| EP-4245765-A2 | TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS | Boehringer Ingelheim Vetmedica GmbH (DE) | 2023-09-20 | — | — | EP | claimed |
| US-11759474-B2 | Use of SGLT-2 inhibitors in the drying-off of non-human mammals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-09-19 | — | — | US | claimed |
| US-20110237532-A1 | 1-[(3-CYANO-PYRIDIN-2-YL)METHYL]-3-METHYL-7-(2-BUTYN-1-YL)-8-[3-(R)-AMINO-PIPERIDIN-1-YL]-XANTHINE FOR THE TREATMENT OF A METABOLIC DISORDER OF A PREDOMINANTLY CARNIVOROUS NON-HUMAN ANIMAL | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2011-09-29 | — | — | US | claimed |
| EP-2368552-A1 | 1-[(3-cyano-pyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-[3-(r)-amino-piperidin-1-yl]-xanthine for the treatment of a metabolic disorder of a predominantly carnivorous non-human animal | Boehringer Ingelheim Vetmedica GmbH (DE) | 2011-09-28 | — | — | EP | claimed |
| US-20110195917-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-11 | — | — | US | claimed |
| US-20110046087-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-24 | — | — | US | claimed |
| US-20110046076-A1 | PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-02-24 | — | — | US | claimed |
| US-20100209506-A1 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-19 | — | — | US | claimed |
| US-20100179191-A1 | GLUCOPYRANOSYL-SUBSTITUTED CYCLOPROPYLBENZENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AS SGLT INHIBITORS AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| EP-2054426-A1 | GLUCOPYRANOSYL-SUBSTITUTED CYCLOPROPYLBENZENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AS SGLT INHIBITORS AND PROCESS FOR THEIR MANUFACTURE | Boehringer Ingelheim International GmbH (DE) | 2009-05-06 | — | — | EP | claimed |
| US-20080058379-A1 | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-03-06 | — | — | US | claimed |
| WO-2008020011-A1 | GLUCOPYRANOSYL-SUBSTITUTED CYCLOPROPYLBENZENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS, THEIR USE AS SGLT INHIBITORS AND PROCESS FOR THEIR MANUFACTURE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | WO | claimed |